Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Buy
100
NRIX Quote, Financials, Valuation and Earnings
Last price:
$21.20
Seasonality move
:
-4.23%
Day range:
$20.21 - $22.50
52-week range:
$8.18 - $22.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.17x
P/B ratio:
4.43x
Volume:
6.1M
Avg. volume:
1.9M
1-year change:
0.47%
Market cap:
$1.7B
Revenue:
$54.5M
EPS (TTM):
-$2.97
Analysts' Opinion
-
Consensus RatingNurix Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $27.18, Nurix Therapeutics, Inc. has an estimated upside of 26.58% from its current price of $21.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 30.14% downside risk from its current price of $21.47.
Fair Value
-
According to the consensus of 13 analysts, Nurix Therapeutics, Inc. has 26.58% upside to fair value with a price target of $27.18 per share.
NRIX vs. S&P 500
-
Over the past 5 trading days, Nurix Therapeutics, Inc. has overperformed the S&P 500 by 27.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Nurix Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nurix Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nurix Therapeutics, Inc. reported revenues of $7.9M.
Earnings Growth
-
Nurix Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nurix Therapeutics, Inc. reported earnings per share of -$1.03.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
21.17x
EV / EBIT:
--
EV / Revenue:
15.28x
PEG ratio (5yr expected):
-3.78x
EV / Free cash flow:
-5.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$65.2M
Return On Assets:
-41.94%
Net Income Margin (TTM):
-292.5%
Return On Equity:
-55.52%
Return On Invested Capital:
-51.1%
Operating Margin:
-1157.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-08-31 | 2024-08-31 | 2025-08-31 | 2024-08-31 | 2025-08-31 | |
| Income Statement | ||||||
| Revenue | $68.6M | $56.4M | $83.7M | $12.6M | $7.9M | |
| Gross Profit | $55.7M | $40.5M | $65.2M | $8.4M | $2.9M | |
| Operating Income | -$158.4M | -$193.7M | -$267.2M | -$54.6M | -$91.4M | |
| EBITDA | -$145.5M | -$177.8M | -$248.7M | -$50.5M | -$86.4M | |
| Diluted EPS | -$2.75 | -$2.91 | -$2.97 | -$0.67 | -$1.03 | |
| Period Ending | 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2025-08-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $358.4M | $354.9M | $267.9M | $456M | $440.6M | |
| Total Assets | $493.1M | $459.3M | $308.2M | $513.6M | $522.5M | |
| Current Liabilities | $50.7M | $67.5M | $61.5M | $86.3M | $82.4M | |
| Total Liabilities | $117.9M | $116.8M | $74.4M | $136.7M | $150.2M | |
| Total Equity | $375.2M | $342.5M | $233.8M | $376.9M | $372.3M | |
| Total Debt | -- | $7.7M | $2.6M | $20.6M | $52.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-08-31 | 2024-08-31 | 2025-08-31 | 2024-08-31 | 2025-08-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$146M | -$97.1M | -$230.4M | -$42.2M | -$57.4M | |
| Cash From Investing | $137.7M | -$131.3M | $6.7M | -$21.3M | $50.5M | |
| Cash From Financing | $3.1M | $285.2M | $203.2M | $45.8M | $1.2M | |
| Free Cash Flow | -$154.4M | -$106.9M | -$241.4M | -$44.5M | -$60.1M | |
NRIX
Sector
Market Cap
$1.7B
$28.5M
Price % of 52-Week High
93.55%
51.43%
Dividend Yield
0%
0%
Shareholder Yield
-29.07%
-1.33%
1-Year Price Total Return
0.47%
-21.18%
Beta (5-Year)
1.874
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$17.82
200-day SMA
Buy
Level
$11.57
Bollinger Bands (100)
Buy
Level
8.66 - 13.94
Chaikin Money Flow
Sell
Level
-19.4M
20-day SMA
Buy
Level
$15.56
Relative Strength Index (RSI14)
Buy
Level
82.95
ADX Line
Buy
Level
48.64
Williams %R
Sell
Level
-10.2275
50-day SMA
Buy
Level
$12.67
MACD (12, 26)
Buy
Level
1.88
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
23.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2194)
Sell
CA Score
(Annual)
Level (-1.3554)
Buy
Beneish M-Score
(Annual)
Level (-3.9233)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.9675)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, NRIX has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NRIX average analyst price target in the past 3 months is $27.18.
-
Where Will Nurix Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nurix Therapeutics, Inc. share price will rise to $27.18 per share over the next 12 months.
-
What Do Analysts Say About Nurix Therapeutics, Inc.?
Analysts are divided on their view about Nurix Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nurix Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Nurix Therapeutics, Inc.'s Price Target?
The price target for Nurix Therapeutics, Inc. over the next 1-year time period is forecast to be $27.18 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NRIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nurix Therapeutics, Inc. is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NRIX?
You can purchase shares of Nurix Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nurix Therapeutics, Inc. shares.
-
What Is The Nurix Therapeutics, Inc. Share Price Today?
Nurix Therapeutics, Inc. was last trading at $21.20 per share. This represents the most recent stock quote for Nurix Therapeutics, Inc.. Yesterday, Nurix Therapeutics, Inc. closed at $21.47 per share.
-
How To Buy Nurix Therapeutics, Inc. Stock Online?
In order to purchase Nurix Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NRIX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NRIX
Sector
P/E ratio
--
23.66x
PEG ratio
-3.78x
-0.01x
P/B ratio
4.43x
1.82x
Price / LTM sales
21.17x
1.61x
Growth Metrics
NRIX
Sector
Revenue growth
-37.29%
4.8%
Earnings growth
-52.65%
11.11%
Revenue (5-year growth)
11.88%
6.45%
Earnings forecast
-$0.92
-$0.20
Profitability
NRIX
Sector
Profitability FY 2024
$38.1M
$3.6M
Return on invested capital
-51.1%
-31.15%
Return on assets
-41.94%
-27.72%
Return on equity
-55.52%
-36.72%
Earnings Date
Last Earnings Date
Oct
9
Next Earnings Date
Jan
28
Estimated Next Earnings Date
Jan
8
Balance Sheet
NRIX
Sector
Total cash
$428.8M
$27M
Short term investments
$499.6M
$25.7M
Total assets
$675.4M
$79.7M
Long term debt
$52.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is down 2.47% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 0.6% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is down 7.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
